Global Mometasone Market

Mometasone Comprehensive Study by Prescription (Over the Counter, Prescription type), Route of Administration (Topical, Intranasal), Indication (Inflammatory skin disorders, Asthma), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies), Dosage Form (Nasal spray, Cream, Ointment, Lotion, Solution) Players and Region - Global Market Outlook to 2030

Mometasone Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 7.5%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Mometasone
Mometasone is a corticosteroid that is used to treat a variety of skin conditions as well as asthma. Mometasone diffuses through the cell membrane and stimulates pathways that reduce inflammation in the case of inflammatory skin disorders. Dermatitis, psoriasis, and allergic rhinitis are examples of inflammatory skin disorders. Mometasone market growth is fueled by an increase in the prevalence of inflammatory skin disorders. During the forecast period, the rise in the geriatric population is expected to drive mometasone market growth. Increasing personal aesthetics concerns will boost the mometasone market in the coming decade.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
CAGR7.5%


The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analyst at AMA Research estimates that Global Players will contribute the maximum growth to Global Mometasone market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Glenmark Pharmaceuticals (India), Hikma Pharmaceuticals (United Kingdom), Aurisco Pharma (China), Perrigo Company plc (Ireland), Bayer AG (Germany), Hubei Hengan Fulin Pharmaceutical Co., Ltd. (China), Unilab Chemicals & Pharmaceuticals Pvt. Ltd. (India), Shanghai Pharmaceuticals Holding Co., Ltd. (China), Zhejiang Xianju Pharmaceutical Co., Ltd. (China) and Symbiotec Pharma (India) are some of the key players that are part of study coverage.

Segmentation Overview
AMA Research has segmented the market of Global Mometasone market by and Region.



On the basis of geography, the market of Mometasone has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Prescription, the sub-segment i.e. Over the Counter will boost the Mometasone market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Route of Administration, the sub-segment i.e. Topical will boost the Mometasone market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Indication, the sub-segment i.e. Inflammatory skin disorders will boost the Mometasone market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Distribution Channel, the sub-segment i.e. Hospital Pharmacies will boost the Mometasone market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Dosage Form, the sub-segment i.e. Nasal spray will boost the Mometasone market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Rising Investment by Key Players

Market Growth Drivers:
Increased Prevalence of Inflammatory Skin Disorders, Rise in Geriatric Population and Growing Patient Population Suffering from Asthma

Challenges:
Pricing Competition among Market Players

Restraints:
Side Effects associated with Mometasone

Opportunities:
Increasing Personal Aesthetics Concern and Rising Collaborative Research and Development Activities among Leading Biopharmaceutical Players

Market Leaders and their expansionary development strategies
In November 2023, Organon (NYSE:OGN) and Sempre Health today announced a strategic partnership designed to motivate eligible patients to refill their prescriptions on time and improve adherence through an innovative pricing program that offers personalized support. The new program offered by Sempre Health and Organon will enable eligible patients who refill their prescriptions on time and as prescribed for Dulera™ (mometasone furoate, formoterol fumarate dihydrate) and Asmanex™ (mometasone furoate), to receive discounts on their medications throughout the course of their therapy, with the aim of improving adherence to their medication.
February 2020, Hikma Pharmaceuticals and Glenmark Pharmaceuticals announced a collaboration to commercialize Olopatadine hydrochloride and mometasone furoate nasal spray used in the treatment of seasonal allergic rhinitis.


Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Venture Capitalists and Private Equity Firms, Government Regulatory and Research Organizations and End-Use Industry

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Prescription
  • Over the Counter
  • Prescription type

By Route of Administration
  • Topical
  • Intranasal

By Indication
  • Inflammatory skin disorders
  • Asthma

By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • Online Pharmacies

By Dosage Form
  • Nasal spray
  • Cream
  • Ointment
  • Lotion
  • Solution

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increased Prevalence of Inflammatory Skin Disorders
      • 3.2.2. Rise in Geriatric Population
      • 3.2.3. Growing Patient Population Suffering from Asthma
    • 3.3. Market Challenges
      • 3.3.1. Pricing Competition among Market Players
    • 3.4. Market Trends
      • 3.4.1. Rising Investment by Key Players
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Mometasone, by Prescription, Route of Administration, Indication, Distribution Channel, Dosage Form and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Mometasone (Value)
      • 5.2.1. Global Mometasone by: Prescription (Value)
        • 5.2.1.1. Over the Counter
        • 5.2.1.2. Prescription type
      • 5.2.2. Global Mometasone by: Route of Administration (Value)
        • 5.2.2.1. Topical
        • 5.2.2.2. Intranasal
      • 5.2.3. Global Mometasone by: Indication (Value)
        • 5.2.3.1. Inflammatory skin disorders
        • 5.2.3.2. Asthma
      • 5.2.4. Global Mometasone by: Distribution Channel (Value)
        • 5.2.4.1. Hospital Pharmacies
        • 5.2.4.2. Retail Pharmacies
        • 5.2.4.3. Drug Stores
        • 5.2.4.4. Online Pharmacies
      • 5.2.5. Global Mometasone by: Dosage Form (Value)
        • 5.2.5.1. Nasal spray
        • 5.2.5.2. Cream
        • 5.2.5.3. Ointment
        • 5.2.5.4. Lotion
        • 5.2.5.5. Solution
      • 5.2.6. Global Mometasone Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
  • 6. Mometasone: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Glenmark Pharmaceuticals (India)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Hikma Pharmaceuticals (United Kingdom)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Aurisco Pharma (China)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Perrigo Company plc (Ireland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Bayer AG (Germany)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Hubei Hengan Fulin Pharmaceutical Co., Ltd. (China)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Unilab Chemicals & Pharmaceuticals Pvt. Ltd. (India)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Shanghai Pharmaceuticals Holding Co., Ltd. (China)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Zhejiang Xianju Pharmaceutical Co., Ltd. (China)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Symbiotec Pharma (India)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Mometasone Sale, by Prescription, Route of Administration, Indication, Distribution Channel, Dosage Form and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Mometasone (Value)
      • 7.2.1. Global Mometasone by: Prescription (Value)
        • 7.2.1.1. Over the Counter
        • 7.2.1.2. Prescription type
      • 7.2.2. Global Mometasone by: Route of Administration (Value)
        • 7.2.2.1. Topical
        • 7.2.2.2. Intranasal
      • 7.2.3. Global Mometasone by: Indication (Value)
        • 7.2.3.1. Inflammatory skin disorders
        • 7.2.3.2. Asthma
      • 7.2.4. Global Mometasone by: Distribution Channel (Value)
        • 7.2.4.1. Hospital Pharmacies
        • 7.2.4.2. Retail Pharmacies
        • 7.2.4.3. Drug Stores
        • 7.2.4.4. Online Pharmacies
      • 7.2.5. Global Mometasone by: Dosage Form (Value)
        • 7.2.5.1. Nasal spray
        • 7.2.5.2. Cream
        • 7.2.5.3. Ointment
        • 7.2.5.4. Lotion
        • 7.2.5.5. Solution
      • 7.2.6. Global Mometasone Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Mometasone: by Prescription(USD Million)
  • Table 2. Mometasone Over the Counter , by Region USD Million (2018-2023)
  • Table 3. Mometasone Prescription type , by Region USD Million (2018-2023)
  • Table 4. Mometasone: by Route of Administration(USD Million)
  • Table 5. Mometasone Topical , by Region USD Million (2018-2023)
  • Table 6. Mometasone Intranasal , by Region USD Million (2018-2023)
  • Table 7. Mometasone: by Indication(USD Million)
  • Table 8. Mometasone Inflammatory skin disorders , by Region USD Million (2018-2023)
  • Table 9. Mometasone Asthma , by Region USD Million (2018-2023)
  • Table 10. Mometasone: by Distribution Channel(USD Million)
  • Table 11. Mometasone Hospital Pharmacies , by Region USD Million (2018-2023)
  • Table 12. Mometasone Retail Pharmacies , by Region USD Million (2018-2023)
  • Table 13. Mometasone Drug Stores , by Region USD Million (2018-2023)
  • Table 14. Mometasone Online Pharmacies , by Region USD Million (2018-2023)
  • Table 15. Mometasone: by Dosage Form(USD Million)
  • Table 16. Mometasone Nasal spray , by Region USD Million (2018-2023)
  • Table 17. Mometasone Cream , by Region USD Million (2018-2023)
  • Table 18. Mometasone Ointment , by Region USD Million (2018-2023)
  • Table 19. Mometasone Lotion , by Region USD Million (2018-2023)
  • Table 20. Mometasone Solution , by Region USD Million (2018-2023)
  • Table 21. South America Mometasone, by Country USD Million (2018-2023)
  • Table 22. South America Mometasone, by Prescription USD Million (2018-2023)
  • Table 23. South America Mometasone, by Route of Administration USD Million (2018-2023)
  • Table 24. South America Mometasone, by Indication USD Million (2018-2023)
  • Table 25. South America Mometasone, by Distribution Channel USD Million (2018-2023)
  • Table 26. South America Mometasone, by Dosage Form USD Million (2018-2023)
  • Table 27. Brazil Mometasone, by Prescription USD Million (2018-2023)
  • Table 28. Brazil Mometasone, by Route of Administration USD Million (2018-2023)
  • Table 29. Brazil Mometasone, by Indication USD Million (2018-2023)
  • Table 30. Brazil Mometasone, by Distribution Channel USD Million (2018-2023)
  • Table 31. Brazil Mometasone, by Dosage Form USD Million (2018-2023)
  • Table 32. Argentina Mometasone, by Prescription USD Million (2018-2023)
  • Table 33. Argentina Mometasone, by Route of Administration USD Million (2018-2023)
  • Table 34. Argentina Mometasone, by Indication USD Million (2018-2023)
  • Table 35. Argentina Mometasone, by Distribution Channel USD Million (2018-2023)
  • Table 36. Argentina Mometasone, by Dosage Form USD Million (2018-2023)
  • Table 37. Rest of South America Mometasone, by Prescription USD Million (2018-2023)
  • Table 38. Rest of South America Mometasone, by Route of Administration USD Million (2018-2023)
  • Table 39. Rest of South America Mometasone, by Indication USD Million (2018-2023)
  • Table 40. Rest of South America Mometasone, by Distribution Channel USD Million (2018-2023)
  • Table 41. Rest of South America Mometasone, by Dosage Form USD Million (2018-2023)
  • Table 42. Asia Pacific Mometasone, by Country USD Million (2018-2023)
  • Table 43. Asia Pacific Mometasone, by Prescription USD Million (2018-2023)
  • Table 44. Asia Pacific Mometasone, by Route of Administration USD Million (2018-2023)
  • Table 45. Asia Pacific Mometasone, by Indication USD Million (2018-2023)
  • Table 46. Asia Pacific Mometasone, by Distribution Channel USD Million (2018-2023)
  • Table 47. Asia Pacific Mometasone, by Dosage Form USD Million (2018-2023)
  • Table 48. China Mometasone, by Prescription USD Million (2018-2023)
  • Table 49. China Mometasone, by Route of Administration USD Million (2018-2023)
  • Table 50. China Mometasone, by Indication USD Million (2018-2023)
  • Table 51. China Mometasone, by Distribution Channel USD Million (2018-2023)
  • Table 52. China Mometasone, by Dosage Form USD Million (2018-2023)
  • Table 53. Japan Mometasone, by Prescription USD Million (2018-2023)
  • Table 54. Japan Mometasone, by Route of Administration USD Million (2018-2023)
  • Table 55. Japan Mometasone, by Indication USD Million (2018-2023)
  • Table 56. Japan Mometasone, by Distribution Channel USD Million (2018-2023)
  • Table 57. Japan Mometasone, by Dosage Form USD Million (2018-2023)
  • Table 58. India Mometasone, by Prescription USD Million (2018-2023)
  • Table 59. India Mometasone, by Route of Administration USD Million (2018-2023)
  • Table 60. India Mometasone, by Indication USD Million (2018-2023)
  • Table 61. India Mometasone, by Distribution Channel USD Million (2018-2023)
  • Table 62. India Mometasone, by Dosage Form USD Million (2018-2023)
  • Table 63. South Korea Mometasone, by Prescription USD Million (2018-2023)
  • Table 64. South Korea Mometasone, by Route of Administration USD Million (2018-2023)
  • Table 65. South Korea Mometasone, by Indication USD Million (2018-2023)
  • Table 66. South Korea Mometasone, by Distribution Channel USD Million (2018-2023)
  • Table 67. South Korea Mometasone, by Dosage Form USD Million (2018-2023)
  • Table 68. Taiwan Mometasone, by Prescription USD Million (2018-2023)
  • Table 69. Taiwan Mometasone, by Route of Administration USD Million (2018-2023)
  • Table 70. Taiwan Mometasone, by Indication USD Million (2018-2023)
  • Table 71. Taiwan Mometasone, by Distribution Channel USD Million (2018-2023)
  • Table 72. Taiwan Mometasone, by Dosage Form USD Million (2018-2023)
  • Table 73. Australia Mometasone, by Prescription USD Million (2018-2023)
  • Table 74. Australia Mometasone, by Route of Administration USD Million (2018-2023)
  • Table 75. Australia Mometasone, by Indication USD Million (2018-2023)
  • Table 76. Australia Mometasone, by Distribution Channel USD Million (2018-2023)
  • Table 77. Australia Mometasone, by Dosage Form USD Million (2018-2023)
  • Table 78. Rest of Asia-Pacific Mometasone, by Prescription USD Million (2018-2023)
  • Table 79. Rest of Asia-Pacific Mometasone, by Route of Administration USD Million (2018-2023)
  • Table 80. Rest of Asia-Pacific Mometasone, by Indication USD Million (2018-2023)
  • Table 81. Rest of Asia-Pacific Mometasone, by Distribution Channel USD Million (2018-2023)
  • Table 82. Rest of Asia-Pacific Mometasone, by Dosage Form USD Million (2018-2023)
  • Table 83. Europe Mometasone, by Country USD Million (2018-2023)
  • Table 84. Europe Mometasone, by Prescription USD Million (2018-2023)
  • Table 85. Europe Mometasone, by Route of Administration USD Million (2018-2023)
  • Table 86. Europe Mometasone, by Indication USD Million (2018-2023)
  • Table 87. Europe Mometasone, by Distribution Channel USD Million (2018-2023)
  • Table 88. Europe Mometasone, by Dosage Form USD Million (2018-2023)
  • Table 89. Germany Mometasone, by Prescription USD Million (2018-2023)
  • Table 90. Germany Mometasone, by Route of Administration USD Million (2018-2023)
  • Table 91. Germany Mometasone, by Indication USD Million (2018-2023)
  • Table 92. Germany Mometasone, by Distribution Channel USD Million (2018-2023)
  • Table 93. Germany Mometasone, by Dosage Form USD Million (2018-2023)
  • Table 94. France Mometasone, by Prescription USD Million (2018-2023)
  • Table 95. France Mometasone, by Route of Administration USD Million (2018-2023)
  • Table 96. France Mometasone, by Indication USD Million (2018-2023)
  • Table 97. France Mometasone, by Distribution Channel USD Million (2018-2023)
  • Table 98. France Mometasone, by Dosage Form USD Million (2018-2023)
  • Table 99. Italy Mometasone, by Prescription USD Million (2018-2023)
  • Table 100. Italy Mometasone, by Route of Administration USD Million (2018-2023)
  • Table 101. Italy Mometasone, by Indication USD Million (2018-2023)
  • Table 102. Italy Mometasone, by Distribution Channel USD Million (2018-2023)
  • Table 103. Italy Mometasone, by Dosage Form USD Million (2018-2023)
  • Table 104. United Kingdom Mometasone, by Prescription USD Million (2018-2023)
  • Table 105. United Kingdom Mometasone, by Route of Administration USD Million (2018-2023)
  • Table 106. United Kingdom Mometasone, by Indication USD Million (2018-2023)
  • Table 107. United Kingdom Mometasone, by Distribution Channel USD Million (2018-2023)
  • Table 108. United Kingdom Mometasone, by Dosage Form USD Million (2018-2023)
  • Table 109. Netherlands Mometasone, by Prescription USD Million (2018-2023)
  • Table 110. Netherlands Mometasone, by Route of Administration USD Million (2018-2023)
  • Table 111. Netherlands Mometasone, by Indication USD Million (2018-2023)
  • Table 112. Netherlands Mometasone, by Distribution Channel USD Million (2018-2023)
  • Table 113. Netherlands Mometasone, by Dosage Form USD Million (2018-2023)
  • Table 114. Rest of Europe Mometasone, by Prescription USD Million (2018-2023)
  • Table 115. Rest of Europe Mometasone, by Route of Administration USD Million (2018-2023)
  • Table 116. Rest of Europe Mometasone, by Indication USD Million (2018-2023)
  • Table 117. Rest of Europe Mometasone, by Distribution Channel USD Million (2018-2023)
  • Table 118. Rest of Europe Mometasone, by Dosage Form USD Million (2018-2023)
  • Table 119. MEA Mometasone, by Country USD Million (2018-2023)
  • Table 120. MEA Mometasone, by Prescription USD Million (2018-2023)
  • Table 121. MEA Mometasone, by Route of Administration USD Million (2018-2023)
  • Table 122. MEA Mometasone, by Indication USD Million (2018-2023)
  • Table 123. MEA Mometasone, by Distribution Channel USD Million (2018-2023)
  • Table 124. MEA Mometasone, by Dosage Form USD Million (2018-2023)
  • Table 125. Middle East Mometasone, by Prescription USD Million (2018-2023)
  • Table 126. Middle East Mometasone, by Route of Administration USD Million (2018-2023)
  • Table 127. Middle East Mometasone, by Indication USD Million (2018-2023)
  • Table 128. Middle East Mometasone, by Distribution Channel USD Million (2018-2023)
  • Table 129. Middle East Mometasone, by Dosage Form USD Million (2018-2023)
  • Table 130. Africa Mometasone, by Prescription USD Million (2018-2023)
  • Table 131. Africa Mometasone, by Route of Administration USD Million (2018-2023)
  • Table 132. Africa Mometasone, by Indication USD Million (2018-2023)
  • Table 133. Africa Mometasone, by Distribution Channel USD Million (2018-2023)
  • Table 134. Africa Mometasone, by Dosage Form USD Million (2018-2023)
  • Table 135. North America Mometasone, by Country USD Million (2018-2023)
  • Table 136. North America Mometasone, by Prescription USD Million (2018-2023)
  • Table 137. North America Mometasone, by Route of Administration USD Million (2018-2023)
  • Table 138. North America Mometasone, by Indication USD Million (2018-2023)
  • Table 139. North America Mometasone, by Distribution Channel USD Million (2018-2023)
  • Table 140. North America Mometasone, by Dosage Form USD Million (2018-2023)
  • Table 141. United States Mometasone, by Prescription USD Million (2018-2023)
  • Table 142. United States Mometasone, by Route of Administration USD Million (2018-2023)
  • Table 143. United States Mometasone, by Indication USD Million (2018-2023)
  • Table 144. United States Mometasone, by Distribution Channel USD Million (2018-2023)
  • Table 145. United States Mometasone, by Dosage Form USD Million (2018-2023)
  • Table 146. Canada Mometasone, by Prescription USD Million (2018-2023)
  • Table 147. Canada Mometasone, by Route of Administration USD Million (2018-2023)
  • Table 148. Canada Mometasone, by Indication USD Million (2018-2023)
  • Table 149. Canada Mometasone, by Distribution Channel USD Million (2018-2023)
  • Table 150. Canada Mometasone, by Dosage Form USD Million (2018-2023)
  • Table 151. Mexico Mometasone, by Prescription USD Million (2018-2023)
  • Table 152. Mexico Mometasone, by Route of Administration USD Million (2018-2023)
  • Table 153. Mexico Mometasone, by Indication USD Million (2018-2023)
  • Table 154. Mexico Mometasone, by Distribution Channel USD Million (2018-2023)
  • Table 155. Mexico Mometasone, by Dosage Form USD Million (2018-2023)
  • Table 156. Company Basic Information, Sales Area and Its Competitors
  • Table 157. Company Basic Information, Sales Area and Its Competitors
  • Table 158. Company Basic Information, Sales Area and Its Competitors
  • Table 159. Company Basic Information, Sales Area and Its Competitors
  • Table 160. Company Basic Information, Sales Area and Its Competitors
  • Table 161. Company Basic Information, Sales Area and Its Competitors
  • Table 162. Company Basic Information, Sales Area and Its Competitors
  • Table 163. Company Basic Information, Sales Area and Its Competitors
  • Table 164. Company Basic Information, Sales Area and Its Competitors
  • Table 165. Company Basic Information, Sales Area and Its Competitors
  • Table 166. Mometasone: by Prescription(USD Million)
  • Table 167. Mometasone Over the Counter , by Region USD Million (2025-2030)
  • Table 168. Mometasone Prescription type , by Region USD Million (2025-2030)
  • Table 169. Mometasone: by Route of Administration(USD Million)
  • Table 170. Mometasone Topical , by Region USD Million (2025-2030)
  • Table 171. Mometasone Intranasal , by Region USD Million (2025-2030)
  • Table 172. Mometasone: by Indication(USD Million)
  • Table 173. Mometasone Inflammatory skin disorders , by Region USD Million (2025-2030)
  • Table 174. Mometasone Asthma , by Region USD Million (2025-2030)
  • Table 175. Mometasone: by Distribution Channel(USD Million)
  • Table 176. Mometasone Hospital Pharmacies , by Region USD Million (2025-2030)
  • Table 177. Mometasone Retail Pharmacies , by Region USD Million (2025-2030)
  • Table 178. Mometasone Drug Stores , by Region USD Million (2025-2030)
  • Table 179. Mometasone Online Pharmacies , by Region USD Million (2025-2030)
  • Table 180. Mometasone: by Dosage Form(USD Million)
  • Table 181. Mometasone Nasal spray , by Region USD Million (2025-2030)
  • Table 182. Mometasone Cream , by Region USD Million (2025-2030)
  • Table 183. Mometasone Ointment , by Region USD Million (2025-2030)
  • Table 184. Mometasone Lotion , by Region USD Million (2025-2030)
  • Table 185. Mometasone Solution , by Region USD Million (2025-2030)
  • Table 186. South America Mometasone, by Country USD Million (2025-2030)
  • Table 187. South America Mometasone, by Prescription USD Million (2025-2030)
  • Table 188. South America Mometasone, by Route of Administration USD Million (2025-2030)
  • Table 189. South America Mometasone, by Indication USD Million (2025-2030)
  • Table 190. South America Mometasone, by Distribution Channel USD Million (2025-2030)
  • Table 191. South America Mometasone, by Dosage Form USD Million (2025-2030)
  • Table 192. Brazil Mometasone, by Prescription USD Million (2025-2030)
  • Table 193. Brazil Mometasone, by Route of Administration USD Million (2025-2030)
  • Table 194. Brazil Mometasone, by Indication USD Million (2025-2030)
  • Table 195. Brazil Mometasone, by Distribution Channel USD Million (2025-2030)
  • Table 196. Brazil Mometasone, by Dosage Form USD Million (2025-2030)
  • Table 197. Argentina Mometasone, by Prescription USD Million (2025-2030)
  • Table 198. Argentina Mometasone, by Route of Administration USD Million (2025-2030)
  • Table 199. Argentina Mometasone, by Indication USD Million (2025-2030)
  • Table 200. Argentina Mometasone, by Distribution Channel USD Million (2025-2030)
  • Table 201. Argentina Mometasone, by Dosage Form USD Million (2025-2030)
  • Table 202. Rest of South America Mometasone, by Prescription USD Million (2025-2030)
  • Table 203. Rest of South America Mometasone, by Route of Administration USD Million (2025-2030)
  • Table 204. Rest of South America Mometasone, by Indication USD Million (2025-2030)
  • Table 205. Rest of South America Mometasone, by Distribution Channel USD Million (2025-2030)
  • Table 206. Rest of South America Mometasone, by Dosage Form USD Million (2025-2030)
  • Table 207. Asia Pacific Mometasone, by Country USD Million (2025-2030)
  • Table 208. Asia Pacific Mometasone, by Prescription USD Million (2025-2030)
  • Table 209. Asia Pacific Mometasone, by Route of Administration USD Million (2025-2030)
  • Table 210. Asia Pacific Mometasone, by Indication USD Million (2025-2030)
  • Table 211. Asia Pacific Mometasone, by Distribution Channel USD Million (2025-2030)
  • Table 212. Asia Pacific Mometasone, by Dosage Form USD Million (2025-2030)
  • Table 213. China Mometasone, by Prescription USD Million (2025-2030)
  • Table 214. China Mometasone, by Route of Administration USD Million (2025-2030)
  • Table 215. China Mometasone, by Indication USD Million (2025-2030)
  • Table 216. China Mometasone, by Distribution Channel USD Million (2025-2030)
  • Table 217. China Mometasone, by Dosage Form USD Million (2025-2030)
  • Table 218. Japan Mometasone, by Prescription USD Million (2025-2030)
  • Table 219. Japan Mometasone, by Route of Administration USD Million (2025-2030)
  • Table 220. Japan Mometasone, by Indication USD Million (2025-2030)
  • Table 221. Japan Mometasone, by Distribution Channel USD Million (2025-2030)
  • Table 222. Japan Mometasone, by Dosage Form USD Million (2025-2030)
  • Table 223. India Mometasone, by Prescription USD Million (2025-2030)
  • Table 224. India Mometasone, by Route of Administration USD Million (2025-2030)
  • Table 225. India Mometasone, by Indication USD Million (2025-2030)
  • Table 226. India Mometasone, by Distribution Channel USD Million (2025-2030)
  • Table 227. India Mometasone, by Dosage Form USD Million (2025-2030)
  • Table 228. South Korea Mometasone, by Prescription USD Million (2025-2030)
  • Table 229. South Korea Mometasone, by Route of Administration USD Million (2025-2030)
  • Table 230. South Korea Mometasone, by Indication USD Million (2025-2030)
  • Table 231. South Korea Mometasone, by Distribution Channel USD Million (2025-2030)
  • Table 232. South Korea Mometasone, by Dosage Form USD Million (2025-2030)
  • Table 233. Taiwan Mometasone, by Prescription USD Million (2025-2030)
  • Table 234. Taiwan Mometasone, by Route of Administration USD Million (2025-2030)
  • Table 235. Taiwan Mometasone, by Indication USD Million (2025-2030)
  • Table 236. Taiwan Mometasone, by Distribution Channel USD Million (2025-2030)
  • Table 237. Taiwan Mometasone, by Dosage Form USD Million (2025-2030)
  • Table 238. Australia Mometasone, by Prescription USD Million (2025-2030)
  • Table 239. Australia Mometasone, by Route of Administration USD Million (2025-2030)
  • Table 240. Australia Mometasone, by Indication USD Million (2025-2030)
  • Table 241. Australia Mometasone, by Distribution Channel USD Million (2025-2030)
  • Table 242. Australia Mometasone, by Dosage Form USD Million (2025-2030)
  • Table 243. Rest of Asia-Pacific Mometasone, by Prescription USD Million (2025-2030)
  • Table 244. Rest of Asia-Pacific Mometasone, by Route of Administration USD Million (2025-2030)
  • Table 245. Rest of Asia-Pacific Mometasone, by Indication USD Million (2025-2030)
  • Table 246. Rest of Asia-Pacific Mometasone, by Distribution Channel USD Million (2025-2030)
  • Table 247. Rest of Asia-Pacific Mometasone, by Dosage Form USD Million (2025-2030)
  • Table 248. Europe Mometasone, by Country USD Million (2025-2030)
  • Table 249. Europe Mometasone, by Prescription USD Million (2025-2030)
  • Table 250. Europe Mometasone, by Route of Administration USD Million (2025-2030)
  • Table 251. Europe Mometasone, by Indication USD Million (2025-2030)
  • Table 252. Europe Mometasone, by Distribution Channel USD Million (2025-2030)
  • Table 253. Europe Mometasone, by Dosage Form USD Million (2025-2030)
  • Table 254. Germany Mometasone, by Prescription USD Million (2025-2030)
  • Table 255. Germany Mometasone, by Route of Administration USD Million (2025-2030)
  • Table 256. Germany Mometasone, by Indication USD Million (2025-2030)
  • Table 257. Germany Mometasone, by Distribution Channel USD Million (2025-2030)
  • Table 258. Germany Mometasone, by Dosage Form USD Million (2025-2030)
  • Table 259. France Mometasone, by Prescription USD Million (2025-2030)
  • Table 260. France Mometasone, by Route of Administration USD Million (2025-2030)
  • Table 261. France Mometasone, by Indication USD Million (2025-2030)
  • Table 262. France Mometasone, by Distribution Channel USD Million (2025-2030)
  • Table 263. France Mometasone, by Dosage Form USD Million (2025-2030)
  • Table 264. Italy Mometasone, by Prescription USD Million (2025-2030)
  • Table 265. Italy Mometasone, by Route of Administration USD Million (2025-2030)
  • Table 266. Italy Mometasone, by Indication USD Million (2025-2030)
  • Table 267. Italy Mometasone, by Distribution Channel USD Million (2025-2030)
  • Table 268. Italy Mometasone, by Dosage Form USD Million (2025-2030)
  • Table 269. United Kingdom Mometasone, by Prescription USD Million (2025-2030)
  • Table 270. United Kingdom Mometasone, by Route of Administration USD Million (2025-2030)
  • Table 271. United Kingdom Mometasone, by Indication USD Million (2025-2030)
  • Table 272. United Kingdom Mometasone, by Distribution Channel USD Million (2025-2030)
  • Table 273. United Kingdom Mometasone, by Dosage Form USD Million (2025-2030)
  • Table 274. Netherlands Mometasone, by Prescription USD Million (2025-2030)
  • Table 275. Netherlands Mometasone, by Route of Administration USD Million (2025-2030)
  • Table 276. Netherlands Mometasone, by Indication USD Million (2025-2030)
  • Table 277. Netherlands Mometasone, by Distribution Channel USD Million (2025-2030)
  • Table 278. Netherlands Mometasone, by Dosage Form USD Million (2025-2030)
  • Table 279. Rest of Europe Mometasone, by Prescription USD Million (2025-2030)
  • Table 280. Rest of Europe Mometasone, by Route of Administration USD Million (2025-2030)
  • Table 281. Rest of Europe Mometasone, by Indication USD Million (2025-2030)
  • Table 282. Rest of Europe Mometasone, by Distribution Channel USD Million (2025-2030)
  • Table 283. Rest of Europe Mometasone, by Dosage Form USD Million (2025-2030)
  • Table 284. MEA Mometasone, by Country USD Million (2025-2030)
  • Table 285. MEA Mometasone, by Prescription USD Million (2025-2030)
  • Table 286. MEA Mometasone, by Route of Administration USD Million (2025-2030)
  • Table 287. MEA Mometasone, by Indication USD Million (2025-2030)
  • Table 288. MEA Mometasone, by Distribution Channel USD Million (2025-2030)
  • Table 289. MEA Mometasone, by Dosage Form USD Million (2025-2030)
  • Table 290. Middle East Mometasone, by Prescription USD Million (2025-2030)
  • Table 291. Middle East Mometasone, by Route of Administration USD Million (2025-2030)
  • Table 292. Middle East Mometasone, by Indication USD Million (2025-2030)
  • Table 293. Middle East Mometasone, by Distribution Channel USD Million (2025-2030)
  • Table 294. Middle East Mometasone, by Dosage Form USD Million (2025-2030)
  • Table 295. Africa Mometasone, by Prescription USD Million (2025-2030)
  • Table 296. Africa Mometasone, by Route of Administration USD Million (2025-2030)
  • Table 297. Africa Mometasone, by Indication USD Million (2025-2030)
  • Table 298. Africa Mometasone, by Distribution Channel USD Million (2025-2030)
  • Table 299. Africa Mometasone, by Dosage Form USD Million (2025-2030)
  • Table 300. North America Mometasone, by Country USD Million (2025-2030)
  • Table 301. North America Mometasone, by Prescription USD Million (2025-2030)
  • Table 302. North America Mometasone, by Route of Administration USD Million (2025-2030)
  • Table 303. North America Mometasone, by Indication USD Million (2025-2030)
  • Table 304. North America Mometasone, by Distribution Channel USD Million (2025-2030)
  • Table 305. North America Mometasone, by Dosage Form USD Million (2025-2030)
  • Table 306. United States Mometasone, by Prescription USD Million (2025-2030)
  • Table 307. United States Mometasone, by Route of Administration USD Million (2025-2030)
  • Table 308. United States Mometasone, by Indication USD Million (2025-2030)
  • Table 309. United States Mometasone, by Distribution Channel USD Million (2025-2030)
  • Table 310. United States Mometasone, by Dosage Form USD Million (2025-2030)
  • Table 311. Canada Mometasone, by Prescription USD Million (2025-2030)
  • Table 312. Canada Mometasone, by Route of Administration USD Million (2025-2030)
  • Table 313. Canada Mometasone, by Indication USD Million (2025-2030)
  • Table 314. Canada Mometasone, by Distribution Channel USD Million (2025-2030)
  • Table 315. Canada Mometasone, by Dosage Form USD Million (2025-2030)
  • Table 316. Mexico Mometasone, by Prescription USD Million (2025-2030)
  • Table 317. Mexico Mometasone, by Route of Administration USD Million (2025-2030)
  • Table 318. Mexico Mometasone, by Indication USD Million (2025-2030)
  • Table 319. Mexico Mometasone, by Distribution Channel USD Million (2025-2030)
  • Table 320. Mexico Mometasone, by Dosage Form USD Million (2025-2030)
  • Table 321. Research Programs/Design for This Report
  • Table 322. Key Data Information from Secondary Sources
  • Table 323. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Mometasone: by Prescription USD Million (2018-2023)
  • Figure 5. Global Mometasone: by Route of Administration USD Million (2018-2023)
  • Figure 6. Global Mometasone: by Indication USD Million (2018-2023)
  • Figure 7. Global Mometasone: by Distribution Channel USD Million (2018-2023)
  • Figure 8. Global Mometasone: by Dosage Form USD Million (2018-2023)
  • Figure 9. South America Mometasone Share (%), by Country
  • Figure 10. Asia Pacific Mometasone Share (%), by Country
  • Figure 11. Europe Mometasone Share (%), by Country
  • Figure 12. MEA Mometasone Share (%), by Country
  • Figure 13. North America Mometasone Share (%), by Country
  • Figure 14. Global Mometasone share by Players 2023 (%)
  • Figure 15. Global Mometasone share by Players (Top 3) 2023(%)
  • Figure 16. Global Mometasone share by Players (Top 5) 2023(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. Glenmark Pharmaceuticals (India) Revenue, Net Income and Gross profit
  • Figure 19. Glenmark Pharmaceuticals (India) Revenue: by Geography 2023
  • Figure 20. Hikma Pharmaceuticals (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 21. Hikma Pharmaceuticals (United Kingdom) Revenue: by Geography 2023
  • Figure 22. Aurisco Pharma (China) Revenue, Net Income and Gross profit
  • Figure 23. Aurisco Pharma (China) Revenue: by Geography 2023
  • Figure 24. Perrigo Company plc (Ireland) Revenue, Net Income and Gross profit
  • Figure 25. Perrigo Company plc (Ireland) Revenue: by Geography 2023
  • Figure 26. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 27. Bayer AG (Germany) Revenue: by Geography 2023
  • Figure 28. Hubei Hengan Fulin Pharmaceutical Co., Ltd. (China) Revenue, Net Income and Gross profit
  • Figure 29. Hubei Hengan Fulin Pharmaceutical Co., Ltd. (China) Revenue: by Geography 2023
  • Figure 30. Unilab Chemicals & Pharmaceuticals Pvt. Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 31. Unilab Chemicals & Pharmaceuticals Pvt. Ltd. (India) Revenue: by Geography 2023
  • Figure 32. Shanghai Pharmaceuticals Holding Co., Ltd. (China) Revenue, Net Income and Gross profit
  • Figure 33. Shanghai Pharmaceuticals Holding Co., Ltd. (China) Revenue: by Geography 2023
  • Figure 34. Zhejiang Xianju Pharmaceutical Co., Ltd. (China) Revenue, Net Income and Gross profit
  • Figure 35. Zhejiang Xianju Pharmaceutical Co., Ltd. (China) Revenue: by Geography 2023
  • Figure 36. Symbiotec Pharma (India) Revenue, Net Income and Gross profit
  • Figure 37. Symbiotec Pharma (India) Revenue: by Geography 2023
  • Figure 38. Global Mometasone: by Prescription USD Million (2025-2030)
  • Figure 39. Global Mometasone: by Route of Administration USD Million (2025-2030)
  • Figure 40. Global Mometasone: by Indication USD Million (2025-2030)
  • Figure 41. Global Mometasone: by Distribution Channel USD Million (2025-2030)
  • Figure 42. Global Mometasone: by Dosage Form USD Million (2025-2030)
  • Figure 43. South America Mometasone Share (%), by Country
  • Figure 44. Asia Pacific Mometasone Share (%), by Country
  • Figure 45. Europe Mometasone Share (%), by Country
  • Figure 46. MEA Mometasone Share (%), by Country
  • Figure 47. North America Mometasone Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Glenmark Pharmaceuticals (India)
  • Hikma Pharmaceuticals (United Kingdom)
  • Aurisco Pharma (China)
  • Perrigo Company plc (Ireland)
  • Bayer AG (Germany)
  • Hubei Hengan Fulin Pharmaceutical Co., Ltd. (China)
  • Unilab Chemicals & Pharmaceuticals Pvt. Ltd. (India)
  • Shanghai Pharmaceuticals Holding Co., Ltd. (China)
  • Zhejiang Xianju Pharmaceutical Co., Ltd. (China)
  • Symbiotec Pharma (India)
Select User Access Type

Key Highlights of Report


Apr 2024 233 Pages 57 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Mometasone Market Quantitative research analysis
Global Mometasone Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Glenmark Pharmaceuticals (India), Hikma Pharmaceuticals (United Kingdom), Aurisco Pharma (China), Perrigo Company plc (Ireland), Bayer AG (Germany), Hubei Hengan Fulin Pharmaceutical Co., Ltd. (China), Unilab Chemicals & Pharmaceuticals Pvt. Ltd. (India), Shanghai Pharmaceuticals Holding Co., Ltd. (China), Zhejiang Xianju Pharmaceutical Co., Ltd. (China) and Symbiotec Pharma (India) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Rising Investment by Key Players" is seen as one of major influencing trends for Mometasone Market during projected period 2023-2030.
The Mometasone market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Mometasone Market Report?

Have a Query? Click Here

Other Related Reports

Blood Pressure Maintenance Supplements Comprehensive Study by Application (Adults, Pregnant Women, Geriatrics), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drugstores, Online Pharma...
$ 3650
Essential Thrombocythemia Comprehensive Study by Application (Hospitals, Emergency Departments, Clinics, Others), Drug (Aspirin, Hydroxyurea, Anagrelide, Interferon), End Users (Above 60 Years People...
$ 3450
Cushing’s Disease Treatment Comprehensive Study by Drug (Ketoconazole, Mitotane, Aminoglutethimide, Metyrapone, Mifepristone, Etomidate, Pasireotide), Cushing’s Syndrome (Iatrogenic Cushing’s Syndrom...
$ 3650
Follicular Lymphoma Drugs Comprehensive Study by Drug (Brand, Generic), Therapy (Mono, Combinational (Tazemetostat, Lenalidomide, CAR-T therapies Kymriah, Yescarta)), Treatment (Radiation, Chemothera...
$ 3650
Warts Comprehensive Study by Drug (Brand, Generic), Type (Common Warts, Flat Warts, Pigmented Warts, Plantar Warts), Treatment (Salicylic acid, Duct tape, Cryotherapy, Urgery, Laser treatment, Electr...
$ 3750
Controlled Substance Comprehensive Study by Type (Opioids, Stimulants, Depressants, Cannabinoids), Treatment (Pain management, Sleep disorders, Depression and anxiety, Seizure, Attention Deficit Hype...
$ 3650